# **Personal History:**

Name	MAENG, CHI HOON
Citizenship	Korea, Republic of
Email	mchihoon@khu.ac.kr
Affiliation	Kyung Hee University, College of Medicine, Department of medicine
	Kyung Hee University Hospital, Department of Medical Oncology and Hematology
Address	(02447) 23, Kyungheedae-ro, Dongdaemun-gu, Seoul
Title	Associate Professor
Telephone	+82-2-958-2965
Fax	+82-2-968-1848

# **Education:**

Mar 1997~Feb 2003	Kyung Hee University, School of Medicine, Seoul, Korea (M.D.)
Mar 2006~Feb 2008	Graduate School, Kyung Hee University, School of Medicine, Seoul, Korea
	Internal Medicine, Graduated with M.S. degree, Prof. Si-Young Kim
Mar 2011~Feb 2013	Graduate School, Sungkyunkwan University College of Medicine, Seoul, Korea
	Internal Medicine, Graduated with Ph.D degree Prof. Keunchil Park

# **Current and previous positions:**

Mar 2003~Feb 2004	Internship program
	Kyung Hee University, School of Medicine,
	Kyung Hee Univesity Hospital, Seoul, Korea
Mar 2004~Feb 2008	Resident program, University, Kyung Hee University, School of Medicine,
	Kyung Hee University Hospital, Seoul, Korea
May 2011~Feb 2013	Clinical fellowship, Division of Hematology/Oncology, Department of Medicine
	Sungkyunkwan University School of Medicine,
	Samsung Medical Center, Seoul, Korea
Mar 2013~Feb 2016	Clinical Assistant Professor, Kyung Hee Univesity Hospital, Seoul, Korea
Mar 2016~Feb 2020	Assistant Professor
Mar 2020~Present	Associate Professor, Division of Medical Oncology-Hematology,
	Department of Internal Medicine, Kyung Hee University Hospital
	Kyung HeeUniversity College of Medicine

## Award:

2012	Hanmi Best Presentation Award (Korean Society of Medical Oncology Annual Meeting)
2018	ESMO ASIA Merit Award
2019	Boryung Academic Award in KSMO 2019 Annual Meeting
2020	대한내과학회 우수논문상

## **Professional organizations and societies:**

Korean Assocation of Internal Medicine (Active member) Korean Society for Medical Oncology (Active member) Korean Cancer Association (Active member) Korean Cancer Study Group (Active member)

- Assistant administrator of the Public Relations Committee

Korean Society for Hospice and Palliative Care (Active member)

- Assistant administrator of the Scientific Committee

American Society of Clinical Oncology (Active member)

European Society of Medical Oncology (Active member)

American Association for Cancer Research (Active member)

Associate editor of Journal of Gastric Cancer

Korean Gastric Cancer Association

- member of the Scientific Committee

국민연금 장애등급 자문위원 (고형암)

인사혁신처 공무원재해보상연금위원회 의학자문위원

#### **PUBLICATIONS**

#### As the first or corresponing author,

1. Perspectives on Professional Burnout and Occupational Stress among Medical Oncologists: A Crosssectional Survey by Korean Society for Medical Oncology (KSMO).

Lee YG, Maeng CH, Kim DY, Kim BS.

Cancer Res Treat. 2020 Oct;52(4):1002-1009

2. Optimal time interval from surgery to adjuvant chemotherapy in gastric cancer.

Ahn GT, Baek SK, Han JJ, Kim HJ, Jeong SJ, Maeng CH.

Oncol Lett. 2020 Oct;20(4):32

3. Pembrolizumab-induced severe oral mucositis in a patient with squamous cell carcinoma of the lung: A case study.

Yoon SY, Han JJ, Baek SK, Kim HJ, Maeng CH.

Lung Cancer. 2020 Sep;147:21-25

4. Practice patterns of multidisciplinary team meetings in Korean cancer care and patient satisfaction with this approach.

Maeng CH, Ahn HK, Oh SY, Lim S, Kim BS, Kim DY.

Korean J Intern Med. 2020 Jan;35(1):205-214

5. The Role of Prophylactic Cranial Irradiation in Patients With Extensive Stage Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.

Maeng CH, Song JU, Shim SR, Lee J. J

Thorac Oncol. 2018 Jun;13(6):840-848. doi: 10.1016/j.jtho.2018.02.024. Epub 2018 Mar 8.

6. A Phase III Study to Compare the Efficacy and Safety of Paclitaxel Versus Irinotecan in Patients with Metastatic or Recurrent Gastric Cancer Who Failed in First-line Therapy (KCSG ST10-01).

Lee KW, Maeng CH, Kim TY, Zang DY, Kim YH, Hwang IG, Oh SC, Chung JS, Song HS, Kim JW, Jeong SJ, Cho JY.

Oncologist. 2018 Aug 20. pii: theoncologist. 2018-0142. doi: 10.1634/theoncologist. 2018-0142. [Epub ahead of print]

7. Pneumatosis cystoides intestinalis associated with sunitinib and a literature review.

Lee YS, Han JJ, Kim SY, Maeng CH.

BMC Cancer. 2017 Nov 9;17(1):732. doi: 10.1186/s12885-017-3744-0. Review.

- 8. Crohn's disease and smoldering multiple myeloma: a case report and literature review. Park SY, Kim JM, Kang HJ, Kim M, Han JJ, Maeng CH, Baek SK, Yoon HJ, Kim SY, Kim HJ. Intest Res. 2017 Apr;15(2):249-254.
- 9. Comparison of total body irradiation (TBI) conditioning with non-TBI for autologous stem cell transplantation in newly diagnosed or relapsed mature T and NK-cell non-Hodgkin lymphoma. Chi Hoon Maeng, Young Hyeh Ko, Do Hoon Lim, Eun Suk Kang, Joon Young Choi, Won Seog Kim, Seok Jin Kim.

Cancer Research and Treatment. Cancer Res TreatCancer Res Treat. 2017;49(1):92-1032.

10. Treatment outcomes and clinical relevance of follicular lymphoma international prognostic index (FLIPI) in Korean follicular lymphoma patients who were treated by chemotherapy.

Chi Hoon Maeng, Sung Woo Ahn, Seong-Yoon Ryu, Sungjun Han, Young Hyeh Ko, Jun Ho Ji, Won Seog Kim, Seok Jin Kim.

Korean J Intern Med. 2016 May;31(3):560-9

11. Radiation recall phenomenon presenting as myositis triggered by carboplatin plus paclitaxel and related literature review.

Maeng CH, Park JS, Lee SA, Kim DH, Yun DH, Yoo SD, Kim HS, Chon J. J Cancer Res Ther. 2014 Oct-Dec;10(4):1093-7. doi: 10.4103/0973-1482.146090.

12. High-throughput molecular genotyping for small biopsy samples in advanced non-small cell lung cancer patients.

Maeng CH, Lee HY, Kim YW, Choi MK, Hong JY, Jung HA, Lee KS, Kim H, Kwon OJ, Sun JM, Ahn JS, Park K, Um SW, Ahn MJ.

Anticancer Res. 2013 Nov;33(11):5127-33.

13. Effects of single nucleotide polymorphisms on treatment outcomes and toxicity in patients treated with sunitinib.

Maeng CH, Yi JH, Lee J, Hong JY, Choi MK, Jung HA, Park JO, Park SH, Park YS, Kang WK, Lim HY.

Anticancer Res. 2013 Oct;33(10):4619-26.

14. High-throughput genotyping in metastatic esophageal squamous cell carcinoma identifies phosphoinositide-3-kinase and BRAF mutations.

Maeng CH, Lee J, van Hummelen P, Park SH, Palescandolo E, Jang J, Park HY, Kang SY, MacConaill L, Kim KM, Shim YM.

PLoS One. 2012;7(8):e41655.

15. A case of organizing pneumonia associated with rituximab.

Maeng CH, Chin SO, Yang BH, Kim SY, Youn HJ, Cho KS, Baek SK, Lee S. Cancer Res Treat. 2007 Jun;39(2):88-91.

### As a Co-author,

16. Bone Marrow Homeostasis Is Impaired via JAK/STAT and Glucocorticoid Signaling in Cancer Cachexia Model.

- Yu J, Choi S, Park A, Do J, Nam D, Kim Y, Noh J, Lee KY, Maeng CH, Park KS. Cancers (Basel). 2021 Mar 2;13(5):1059
- 17. 2020 Korean guidelines for the management of metastatic prostate cancer. Kim IH, Shin SJ, Kang BW, Kang J, Kim D, Kim M, Kim JY, Kim CK, Kim HJ, Maeng CH, Park K, Park I, Bae WK, Sohn BS, Lee MY, Lee JL, Lee J, Lim ST, Lim JH, Chang H, Jung JY, Choi YJ, Kim YS, Cho J, Joung JY, Park SH, Lee HJ. Korean J Intern Med. 2021 May;36(3):491-514
- 18. 2020 Korean guidelines for the management of metastatic prostate cancer doi: 10.3904/kjim.2020.213. Online ahead of print. Korean J Intern Med. 2021 Feb 10. Kim IH, Shin SJ, Kang BW, Kang J, Kim D, Kim M, Kim JY, Kim CK, Kim HJ, Maeng CH, Park K, Park I, Bae WK, Sohn BS, Lee MY, Lee JL, Lee J, Lim ST, Lim JH, Chang H, Jung JY, Choi YJ, Kim YS, Cho J, Joung JY, Park SH, Lee HJ.
- 19. Stage IV Epstein-Barr Virus-Associated Early Gastric Cancer and Comparative Analysis of Genetic Alterations in Primary and Metastatic Tumors. Kim HJ, Maeng CH, Sung JY, Na K. J Nippon Med Sch. 2020;87(6):350-354. doi: 10.1272/jnms.JNMS.2020\_87-608.
- 20. The Attitudes of Physicians and the General Public toward Prognostic Disclosure of Different Serious Illnesses: a Korean Nationwide Study. Oh SN, Kim YA, Kim YJ, Shim HJ, Song EK, Kang JH, Kwon JH, Lee JL, Lee SN, Maeng CH, Kang EJ, Do YR, Yun HJ, Jung KH, Yun YH. J Korean Med Sci. 2020 Dec 7;35(47):e401. doi: 10.3346/jkms.2020.35.e401.
- 21. Lenvatinib-Induced Acute Pancreatitis in a Patient with Metastatic Thyroid Cancer: A Case Report. Kim HJ, Han JJ, Maeng CH, Baek SK. Int J Gen Med. 2020 Sep 24;13:699-704. doi: 10.2147/IJGM.S272375. eCollection 2020.
- 22. Acute myeloid leukemia with t(11;19)(q23;p13.1) in a patient with a gastrointestinal stromal tumor undergoing imatinib therapy: A case report. Kim HJ, Baek SK, Maeng CH, Kim SY, Park TS, Han JJ. World J Clin Cases. 2020 Apr 6;8(7):1251-1256. doi: 10.12998/wjcc.v8.i7.1251.
- 23. The Impacts of Prognostic Awareness on Mood and Quality of Life Among Patients With Advanced Cancer. Kang E, Kang JH, Koh SJ, Song EK, Shim HJ, Keam B, Maeng CH, Kim YJ, Yun HJ, Jung KH, Kwon JH, Lee SN, Lee JL, Do YR, Min J, Lee J, Choo J, Yun YH. Am J Hosp Palliat Care. 2020 Feb 13:1049909120905789. doi: 10.1177/1049909120905789. [Epub ahead of print]
- 24. Selective Targeting of Cancer Stem Cells (CSCs) Based on Photodynamic Therapy (PDT) Penetration Depth Inhibits Colon Polyp Formation in Mice. Kim JK, Byun MR, Maeng CH, Kim YR, Choi JW. Cancers (Basel). 2020 Jan 14;12(1). pii: E203. doi: 10.3390/cancers12010203.
- 25. Korean Practice Guideline for Gastric Cancer 2018: an Evidence-based, Multi-disciplinary Approach. Guideline Committee of the Korean Gastric Cancer Association (KGCA), Development Working Group & Review Panel.
  - J Gastric Cancer. 2019 Mar;19(1):1-48. doi: 10.5230/jgc.2019.19.e8. Epub 2019 Mar 19.
- 26. Association of illness understanding with advance care planning and end-of-life care preferences for advanced cancer patients and their family members.
  Yoo SH, Lee J, Kang JH, Maeng CH, Kim YJ, Song EK, Koh Y, Yun HJ, Shim HJ, Kwon JH, Nam EM, Kang E, Choo J, Yun YH.
  Support Care Cancer. 2020 Jun;28(6):2959-2967. doi: 10.1007/s00520-019-05174-5. Epub 2019 Nov 26.

- 27. Comparative effectiveness of palliative chemotherapy versus neoadjuvant chemotherapy followed by radical cystectomy versus cystectomy followed by adjuvant chemotherapy versus cystectomy for regional node-positive bladder cancer: A retrospective analysis: KCSG GU 17-03. Bae WK, Lee HJ, Park SH, Kim JH, Kim HJ, Maeng CH, Park I, Sohn BS, Kim JA, Lee KH, Lim DH, Chang H, Kim SM, Kim HY, Song H, Lim S, Byun JH, Jung HA. Cancer Med. 2019 Sep;8(12):5431-5437. doi: 10.1002/cam4.2446. Epub 2019 Jul 29.
- 28. Attitudes of the General Public, Cancer Patients, Family Caregivers, and Physicians toward Advance Care Planning: A Nationwide Survey Prior to the Enforcement of the Life-Sustaining Treatment Decision-Making Act.
  Park HY, Kim YA, Sim JA, Lee J, Ryu H, Lee JL, Maeng CH, Kwon JH, Kim YJ, Nam EM, Shim HJ, Song EK, Jung KH, Kang EJ, Kang JH, Yun YH.
  J Pain Symptom Manage. 2018 Dec 26. pii: S0885-3924(18)31480-5.
  doi:10.1016/j.jpainsymman.2018.12.332. [Epub ahead of print]
- 29. Comparison of attitudes towards five end-of-life care interventions (active pain control, withdrawal of futile life-sustaining treatment, passive euthanasia, active euthanasia and physician-assisted suicide): a multicentred cross-sectional survey of Korean patients with cancer, their family caregivers, physicians and the general Korean population.
  Yun YH, Kim KN, Sim JA, Yoo SH, Kim M, Kim YA, Kang BD, Shim HJ, Song EK, Kang JH, Kwon JH, Lee JL, Nam EM, Maeng CH, Kang EJ, Do YR, Choi YS, Jung KH.
  BMJ Open. 2018 Sep 11;8(9):e020519. doi: 10.1136/bmjopen-2017-020519.
- 30. Priorities of a "good death" according to cancer patients, their family caregivers, physicians, and the general population: a nationwide survey.

  Yun YH, Kim KN, Sim JA, Kang E, Lee J, Choo J, Yoo SH, Kim M, Kim YA, Kang BD, Shim HJ, Song EK, Kang JH, Kwon JH, Lee JL, Lee SN, Maeng CH, Kang EJ, Do YR, Choi YS, Jung KH. Support Care Cancer. 2018 Oct;26(10):3479-3488. doi: 10.1007/s00520-018-4209-y. Epub 2018 Apr 22.
- 31. Efficacy and tolerability of ramucirumab monotherapy or in combination with paclitaxel in gastric cancer patients from the Expanded Access Program Cohort by the Korean Cancer Study Group (KCSG). Jung M, Ryu MH, Oh DY, Kang M, Zang DY, Hwang IG, Lee KW, Kim KH, Shim BY, Song EK, Sym SJ, Han HS, Park YL, Kim JS, Lee HW, Lee MH, Koo DH, Song HS, Lee N, Yang SH, Choi DR, Hong YS, Lee KE, Maeng CH, Baek JH, Kim S, Kim YH, Rha SY, Cho JY, Kang YK. Gastric Cancer. 2018 Sep;21(5):819-830. doi: 10.1007/s10120-018-0806-1. Epub 2018 Feb 9.
- 32. The Prognostic 97 Chemoresponse Gene Signature in Ovarian Cancer.

  Matondo A, Jo YH, Shahid M, Choi TG, Nguyen MN, Nguyen NNY, Akter S, Kang I, Ha J, Maeng CH, Kim SY, Lee JS, Kim J, Kim SS.

  Sci Rep. 2017 Aug 29;7(1):9689. doi: 10.1038/s41598-017-08766-5.
- 33. An 8-gene signature for prediction of prognosis and chemoresponse in non-small cell lung cancer. Shahid M, Choi TG, Nguyen MN, Matondo A, Jo YH, Yoo JY, Nguyen NN, Yun HR, Kim J, Akter S, Kang I, Ha J, Maeng CH, Kim SY, Lee JS, Kim J, Kim SS. Oncotarget. 2016 Dec 27;7(52):86561-86572
- 34. A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and Histology. Yi JH, Kang JH, Hwang IG, Ahn HK, Baek HJ, Lee SI, Lim do H, Won YW, Ji JH, Kim HS, Rha SY, Oh SY, Lee KE, Lim T, Maeng CH, Kim MJ, Kim ST, Lee J, Park JO, Park YS, Lim HY, Kang WK, Park SH.

Cancer Res Treat. 2016 Apr;48(2):553-60.

35. Platelet response during the second cycle of decitabine treatment predicts response and survival for myelodysplastic syndrome patients.

Jung HA, Maeng CH, Kim M, Kim S, Jung CW, Jang JH.

Oncotarget. 2015 Jun 30;6(18):16653-62.

- 36. Thyroid cancer and T lymphoblastic leukemia in crohn disease: a case report and literature review. Byun JM, Baek SK, Yoon HJ, Kim SY, Maeng CH, Park TS, Kim HJ, Choi YY, Um YJ. Lab Med. 2015 Spring;46(2):140-5.
- 37. Liver-targeted cyclosporine A-encapsulated poly (lactic-co-glycolic) acid nanoparticles inhibit hepatitis C virus replication.

Jyothi KR, Beloor J, Jo A, Nguyen MN, Choi TG, Kim JH, Akter S, Lee SK, Maeng CH, Baik HH, Kang I, Ha J, Kim SS.

Int J Nanomedicine. 2015 Jan 30;10:903-21.

38. Clinical features and treatment outcomes of primary cutaneous B-cell lymphoma: a single-center analysis in South Korea.

Kim MJ, Hong ME, Maeng CH, Jung HA, Hong JY, Choi MK, Kim SJ, Ko YH, Kim WS. Int J Hematol. 2015 Mar;101(3):273-8.

39. Changes in the mean corpuscular volume after capecitabine treatment are associated with clinical response and survival in patients with advanced gastric cancer.

Jung HA, Kim HJ, Maeng CH, Park SH, Lee J, Park JO, Park YS, Lim HY, Kang WK. Cancer Res Treat. 2015 Jan;47(1):72-7.

40. Role of induction and consolidation chemotherapy in elderly acute myeloid leukemia patients. Kim SJ, Cheong JW, Kim DY, Lee JH, Lee KH, Kim YK, Kim HJ, Song IC, Jo DY, Lee JO, Bang SM, Park J, Lee JH, Lee WS, Joo YD, Maeng CH, Yoon HJ, Lee NR, Kwak JY, Kim KH, Won JH, Han BR, Zang DY, Moon JH, Sohn SK, Bae SH, Ryoo HM, Kim SY, Lee MH, Min YH; Korean Society of Hematology AML/MDS Working Party.

Int J Hematol. 2014 Aug;100(2):141-51.

41. Prognostic factor analysis in core-binding factor-positive acute myeloid leukemia.

Jung HA, Maeng CH, Park S, Kim SJ, Kim K, Jang JH, Jung CW.

Anticancer Res. 2014 Feb;34(2):1037-45.

42. Nomogram to predict treatment outcome of fluoropyrimidine/platinum-based chemotherapy in metastatic esophageal squamous cell carcinoma. Jung HA, Adenis A, Lee J, Park SH, Maeng CH, Park S, Ahn HK, Shim YM, Penel N, Im YH.

Cancer Res Treat. 2013 Dec;45(4):285-94.

43. The impact of activated p-AKT expression on clinical outcomes in diffuse large B-cell lymphoma: a clinicopathological study of 262 cases.

Hong JY, Hong ME, Choi MK, Kim YS, Chang W, Maeng CH, Park S, Lee SJ, Do IG, Jo JS, Jung SH, Kim SJ, Ko YH, Kim WS.

Ann Oncol. 2014 Jan;25(1):182-8.

44. Positive correlation between baseline PET or PET/CT findings and clinical parameters in multiple myeloma patients.

Park S, Lee SJ, Chang WJ, Maeng CH, Hong JY, Choi MK, Kim YS, Jung CW, Jang JH, Kim SJ, Kim

WS, Choi JY, Kim K.

Acta Haematol. 2014;131(4):193-9.

45. Relationship between bortezomib-containing regimens and the incidence of tuberculosis in patients with myeloma.

Kim K, Kim SJ, Maeng CH.

Blood Res. 2013 Sep;48(3):233-4.

- 46. Clinical implication of Time To Brain Metastasis (TTBM) according to breast cancer subtypes. Ahn HK, Park YH, Lee SJ, Park S, Maeng CH, Park W, Choi DH, Hur SJ, Ahn JS, Im YH. Springerplus. 2013 Mar 28;2(1):136.
- 47. Effect of paclitaxel/carboplatin salvage chemotherapy in noncutaneous versus cutaneous metastatic melanoma.

Chang W, Lee SJ, Park S, Choi MK, Hong JY, Kim YS, Maeng CH, Jung HA, Kim S, Lee J. Melanoma Res. 2013 Apr;23(2):147-51.

48. Prospective analysis of quality of life in elderly patients treated with adjuvant chemotherapy for non-small-cell lung cancer.

Park S, Kim IR, Baek KK, Lee SJ, Chang WJ, Maeng CH, Hong JY, Choi MK, Kim YS, Sun JM, Ahn JS, Park K, Jo J, Jung SH, Ahn MJ.

Ann Oncol. 2013 Jun;24(6):1630-9.

49. Unique perception of clinical trials by Korean cancer patients.

Lee SJ, Park LC, Lee J, Kim S, Choi MK, Hong JY, Park S, Maeng CH, Chang W, Kim YS, Park SH, Park JO, Lim HY, Kang WK, Park YS.

BMC Cancer. 2012 Dec 12;12:594.

50. The impact of baseline and interim PET/CT parameters on clinical outcome in patients with diffuse large B cell lymphoma.

Park S, Moon SH, Park LC, Hwang DW, Ji JH, Maeng CH, Cho SH, Ahn HK, Lee JY, Kim SJ, Choi JY, Kim WS.

Am J Hematol. 2012 Sep;87(9):937-40.

51. Implications of different CA 15-3 levels according to breast cancer subtype at initial diagnosis of recurrent or metastatic breast cancer.

Park S, Ahn HK, Park LC, Hwang DW, Ji JH, Maeng CH, Cho SH, Lee JY, Park KT, Ahn JS, Park YH, Im YH.

Oncology. 2012;82(3):180-7.

52. Aortic thrombosis resolved with enoxaparin in a patient treated with cisplatin-based regimen for small cell lung cancer.

Chin SO, Lee JJ, Hwang YH, Han JJ, Maeng CH, Baek SK, Choi CW. Int J Hematol. 2010 Jun;91(5):892-6.

53. The immunohistochemical overexpression of ribonucleotide reductase regulatory subunit M1 (RRM1) protein is a predictor of shorter survival to gemcitabine-based chemotherapy in advanced non-small cell lung cancer (NSCLC).

Lee JJ, Maeng CH, Baek SK, Kim GY, Yoo JH, Choi CW, Kim YH, Kwak YT, Kim DH, Lee YK, Kim JB, Kim SY.

Lung Cancer.

I hereby certify that this document is an accurate representation of my qualifications.

01 JUNE 2021

MAENG, CHI HOON Signature McMillott